The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells

BACKGROUND: The receptor tyrosine kinase (RTK) EGFR is overexpressed and mutated in NSCLC. These mutations can be targeted by RTK inhibitors (TKIs) such as erlotinib. Chromatin-modifying agents may offer a novel therapeutic approach by sensitizing tumor cells to TKIs. METHODS: The NSCLC cell lines H...

Descripción completa

Detalles Bibliográficos
Autores principales: Greve, Gabriele, Schiffmann, Insa, Pfeifer, Dietmar, Pantic, Milena, Schüler, Julia, Lübbert, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682236/
https://www.ncbi.nlm.nih.gov/pubmed/26675484
http://dx.doi.org/10.1186/s12885-015-1967-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682236/
https://www.ncbi.nlm.nih.gov/pubmed/26675484
http://dx.doi.org/10.1186/s12885-015-1967-5

Ejemplares similares